PROK stock forecast, quote, news & analysis
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes... Show more
Why ProKidney (PROK) Stock Is Down -42% in the Last 30 Days
Key Takeaways
- ProKidney (PROK) shares have fallen roughly 42% over the past 30 days, sliding from about $1.72 to below $1.00 per share.
- The decline accelerated after the company filed a $650 million mixed securities shelf and a $200 million at-the-market (ATM) equity program, intensifying dilution concerns.
- The selloff occurred despite positive clinical momentum, including completed enrollment for the Phase 3 PROACT 1 accelerated approval analysis and a pivotal readout expected in Q2 2027.
- A wide analyst target range ($1 to $12) and a reiterated Sell rating with a $1 target from Bank of America highlight the binary nature of the investment case.
- ProKidney ended Q2 2026 with $181.6 million in cash, cash equivalents, and marketable securities, which management says supports operations into mid-2027.
- For deeper data, explore ProKidney's Price Targets, Earnings, and Forecast pages.
- Discover top-performing trading strategies on Tickeron's Trending AI Robots.
ProKidney (PROK) Company Overview and Market Position
ProKidney Corp. is a late clinical-stage biotechnology company headquartered in Winston-Salem, North Carolina, focused on chronic kidney disease (CKD). Its lead product candidate, rilparencel (also known as REACT), is a first-in-class autologous cell therapy derived from a patient's own kidney cells. The therapy is designed to preserve kidney function and delay or prevent the need for dialysis in patients with advanced CKD and type 2 diabetes.
Rilparencel is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study. The program has regenerative medicine advanced therapy (RMAT) designation from the U.S. Food and Drug Administration, and the FDA has confirmed that eGFR slope can serve as the surrogate endpoint for an accelerated approval pathway. Investors follow PROK closely because the company targets a large unmet medical need, but as a pre-revenue, single-asset biotech, its valuation hinges on binary clinical and regulatory outcomes.
ProKidney (PROK) Stock Price Performance: Last 30 Days vs. Quarter
Over the past 30 days, PROK has fallen approximately 42%, dropping from around $1.72 per share to below $1.00. The most severe declines came in the final days of the period, when the stock slid roughly 12% in a single session to a 52-week low near $1.29 and then continued lower below the $1.00 mark.
The broader quarterly trend has been similarly weak. At the start of August, PROK traded near $1.60. The shares rallied to about $2.01 in early September before giving back those gains through September and October. Over the trailing three months, the stock has declined roughly 35% to 40%, reflecting a persistent downtrend punctuated by brief rebounds.
What Drove PROK Stock Price in the Last 30 Days
The primary catalyst behind the recent slide was a financing announcement. In late October, ProKidney filed a $650 million mixed securities shelf registration with the SEC, including a sales agreement for an at-the-market offering of up to $200 million of Class A common stock through Jefferies. For a pre-revenue company already burning cash, the prospect of additional share issuance triggered immediate dilution concerns among investors.
The financing news compounded existing pressure. Around the same time, Citi lowered its price target on PROK to $8 from $10 while maintaining a Buy rating, and Bank of America Securities reiterated a Sell rating with a $1 price target. The wide dispersion in analyst targets reflects uncertainty about the timing and outcome of the Phase 3 program.
These headwinds outweighed otherwise positive developments in the same window, including eight abstracts presented at the American Society of Nephrology (ASN) Kidney Week 2026 supporting rilparencel's mechanism of action and a virtual key opinion leader event recapping that data. Broader weakness in small-cap and pre-revenue biotechnology stocks also contributed to the selling pressure.
What Drove PROK Stock Performance Over the Last Quarter
The quarterly decline reflects a clash between clinical progress and funding risk. On the operational side, ProKidney completed enrollment of patients contributing to the PROACT 1 accelerated approval efficacy analysis, reaffirmed its guidance for a pivotal eGFR slope topline readout in Q2 2027, and presented converging mechanistic evidence at ASN Kidney Week. These milestones support the long-term thesis.
Against that backdrop, however, investors have focused on the company's cash runway and the likelihood of future equity raises. With rising research and development spending and minimal revenue, the $650 million shelf and ATM program signal that additional dilution is probable before key data readouts arrive. The stock's slide toward and then below $1.00 has also drawn attention to Nasdaq minimum bid price considerations. This tension between a potentially transformative pipeline and near-term financing overhang has defined the quarter's downward trend.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots from a platform that hosts hundreds of automated strategies trading thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving traders a focused view of strategies that are currently generating interest. Each bot operates with its own approach, timeframe, and performance metrics, so no two are exactly alike. For investors seeking a data-driven way to monitor names like PROK and the broader market, exploring this curated list can offer a useful starting point.
PROK Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important near-term catalyst is the company's quarterly earnings report and any updated guidance on enrollment, spending, and cash runway. Investors will also watch for completion of full enrollment for the PROACT 1 confirmatory analysis, expected in the second half of 2026, as a precursor to the pivotal eGFR slope readout scheduled for Q2 2027.
On the financing front, the pace and terms of any drawdown under the ATM program will be closely monitored, as continued issuance could pressure the share price. Regulatory milestones, including ongoing FDA interactions under the RMAT designation, and analyst rating or target changes will also influence sentiment. Finally, the performance of the broader small-cap biotechnology sector and interest-rate expectations remain relevant macro factors for this high-beta, pre-revenue stock.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PROK in downward trend: price dove below 50-day moving average on October 12, 2026
PROK moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend. In 50 of 55 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PROK as a result. In 74 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for PROK turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 45 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PROK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for PROK entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PROK's RSI Oscillator exited the oversold zone, 24 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 69 cases where PROK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +7.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where PROK advanced for three days, in 202 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
PROK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.270) is normal, around the industry mean (3.498). P/E Ratio (-2.073) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (344.828) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. PROK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PROK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology